<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554164</url>
  </required_header>
  <id_info>
    <org_study_id>PETAL trial</org_study_id>
    <secondary_id>EudraCT-Number 2006-001641-33</secondary_id>
    <secondary_id>Krebshilfe Grant 107592</secondary_id>
    <nct_id>NCT00554164</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas</brief_title>
  <acronym>PETAL</acronym>
  <official_title>Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the PETAL trial is to determine whether patients with aggressive
      non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of
      chemotherapy benefit from a change of the treatment protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron emission tomography performed after two cycles of (R-)CHOP chemotherapy
      (interim-PET) has been shown to predict long-term outcome in patients with aggressive
      non-Hodgkin's lymphomas. Patients with early normalization of pathological PET findings have
      an excellent prognosis, while patients with a persistently pathological PET scan have a high
      risk of non-response or relapse.

      Patients with a negative interim-PET scan (part A of the trial) will be randomized to receive
      either another four cycles of the (R-)CHOP regimen (arm A1) or four cycles of the (R-)CHOP
      regimen plus two additional doses of rituximab (arm A2). Randomisation in part A of the trial
      was stopped when the number of patients required was reached (128 patients in each treatment
      arm). Since then patients have been uniformly treated according to arm A2.

      Patients with a persistently positive interim-PET scan (part B of the trial) will be
      randomized to either continue treatment with another six (R-)CHOP cycles (arm B1) or switch
      to an alternative protocol used for the treatment of Burkitt's lymphoma (arm B2: six blocks
      according to the so-called B-ALL protocol of the German ALL study group).

      Patients refractory to or relapsing within two years after treatment according to parts A or
      B of the trial will receive age-adapted salvage protocols (patients &lt; 60 years: high-dose
      chemotherapy with autologous stem cell transplantation; patients &gt; 60 years: (R-)ESHAP
      protocol)(part C of the trial).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, overall survival, disease-free survival, toxicity, quality of life</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1073</enrollment>
  <condition>Lymphoma, High-grade</condition>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six cycles of the (R-)CHOP regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six blocks of the B-ALL protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four cycles of the (R-)CHOP regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R-)CHOP protocol</intervention_name>
    <description>Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).</description>
    <arm_group_label>B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-ALL protocol</intervention_name>
    <description>Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).</description>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R-)CHOP protocol</intervention_name>
    <description>Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R-)CHOP protocol</intervention_name>
    <description>Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aggressive B-cell or T-cell non-Hodgkin's lymphoma

          -  Pathological pre-treatment PET scan

          -  Performance status ECOG 0-3

          -  Age 18 - 80 years

          -  Ability to understand the purpose of the study and act accordingly

          -  Willingness to use adequate contraception

          -  Informed consent

        Exclusion Criteria:

          -  Burkitt's lymphoma

          -  Primary central nervous system lymphoma

          -  Previous chemo- and/or radiotherapy

          -  Other cancer within preceding 5 years

          -  HIV infection, active viral hepatitis or other uncontrolled infection

          -  Other medical conditions precluding administration of planned therapy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Duehrsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology, University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Ulrich Duehrsen</investigator_full_name>
    <investigator_title>Prof. Dr. Ulrich Duehrsen</investigator_title>
  </responsible_party>
  <keyword>Aggressive non-Hodgkin's lymphoma</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

